Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection

Youssef, S., Lavian, J., Lee, E. Y., Fan, W., & Bordone, L. A. (2023). Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection. Journal of the American Academy of Dermatology, 88(5), 1125–1127. https://doi.org/10.1016/j.jaad.2022.05.005
Authors:
Soundos Youssef
Jonathan Lavian
Eunice Lee
Weijia Fan
Lindsey A. Bordone
Affiliated Authors:
Soundos Youssef
Eunice Lee
Weijia Fan
Lindsey A. Bordone
Author Keywords:
covid-19 infection
jak inhibitor
sars-cov-2
alopecia areata
tofacitinib
Publication Type:
Article
Unique ID:
10.1016/j.jaad.2022.05.005
PMID:
Publication Date:
Data Source:
OpenAlex

Record Created: